$4.650
+0.051 (+1.09%)收盘时
TMCI 资讯
TMCI 事件
Treace Medical Reports Q2 Revenue of $45.38M
Reports Q2 revenue $45.38M, consensus $43.92M. "We are pleased with our second quarter results which were driven by accelerating year-over-year case volumes and market share gains resulting from increasing surgeon adoption of our comprehensive bunion portfolio as well as our expanding line of new technologies - now providing us access to a broader range of procedures throughout the foot & ankle," said John T. Treace, CEO and Chairman of Treace Medical. "We continue to focus on investing in growth initiatives to leverage our expanded portfolio, while driving profitability, positioning us for stronger growth in the second half of the year."
Company Raises 2026 Revenue Guidance to $204M-$212M
$221.8M. The company said, "The Company is raising its full-year 2026 revenue guidance to be in the range of $204 million to $212 million, representing a decline of 4% to 0% compared to full-year 2025. This compares to previous revenue guidance of $202 million to $212 million. The Company is updating its expectation of a loss in Adjusted EBITDA in the range of $3.0 million to $5.0 million for full year 2026, as compared to previous guidance of a loss in the range of $4.0 million to $6.0 million. The Company reported a loss of $3.9 million in the full-year 2025."
Treace Medical Successfully Completes First HyperPlate XM Implant Case
Treace Medical Concepts announced the successful completion of the first case utilizing its HyperPlate XM Dynamic Compression Locking Implant. "The launch of HyperPlate XM implants marks another important step in the continued expansion of our market-leading bunion and midfoot portfolio," said John Treace, CEO and Chairman of Treace. "As we highlighted earlier this year, we remain focused on expanding our procedural reach broadly throughout the foot and ankle. HyperPlate XM implants are an example of that strategy in action, providing surgeons with another innovative solution that complements our existing technologies and supports the growing adoption of our expanding portfolio. We believe HyperPlate XM implants, together with our SuperBite Compression Screws platform, strengthens our ability to participate in a larger addressable market, drive increased procedural utilization, and deepen customer engagement, while further advancing Treace as a comprehensive foot and ankle technology partner."
Treace Medical Reports Q1 Revenue of $47.2M
Reports Q1 revenue $47.2M, consensus $46.05M. "We are encouraged by the growing demand for our comprehensive portfolio of best-in-class bunion and midfoot correction systems, including our new products, which expand our addressable procedure opportunities across our growing surgeon base," said John T. Treace, CEO and Chairman of Treace Medical. "In the first quarter, we continued to take market share and grow year-over-year case volumes. We remain focused on driving surgeon adoption of our broadened portfolio and commercializing our 2026 new product launches while advancing a robust pipeline of future product innovations. With continued focus on commercial execution and operational discipline, we believe we are well positioned to drive further share gains and return to stronger growth in the back half of the year."
Treace Expects FY26 Adjusted EBITDA of $4M-$6M
Backs FY26 adjusted EBITDA view $4M-$6M. The company said, "The Company reiterates its expectation for a reduction in cash usage of approximately 50% for full-year 2026 as compared to the full year 2025. The Company's full-year 2026 guidance reflects continued case volume growth, offset by continued headwinds from demand driven product and price mix shift within Treace's expanded product portfolio."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。